ProMéxico MIM

Novartis México, a pharmaceutical company from Switzerland invested in 2017 about 10 million dollars in research and development, in accordance with its commitment 2015-2020 of achieving 50 million dollars invested in the country. The projects include the final phases of the upcoming launchings in Oncology and Migraine. Mexico will be the support center for the Americas, including the United States.

In 2017, the North American pharmaceutical Company, informed about its investment of 9.3 million dollars for the plant at Toluca, Estado de México. The project will include new production lines and a packaging line.